Opinion|Videos|January 28, 2025
Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
Author(s)Jeffrey V. Matous, MD
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.
Advertisement
Video content above is prompted by the following:
- What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
- Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
- The Potential Role of Screening for Atrial Fibrillation
September 16th 2025
- Remote Patient Monitoring and Artificial Intelligence
September 16th 2025
- Reassurance in Breast Cancer Survivorship: Adriana Olivo, NP
September 15th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5